Biostage Appoints Ron Packard to Board of Directors
10 avr. 2023 09h30 HE
|
Biostage, Inc.
HOLLISTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
Stella Diagnostics CEO Discusses Competitive Advantage in Early Cancer Detection During Audio Interview with SmallCapVoice.com
15 févr. 2022 08h00 HE
|
Stella Diagnostics, Inc. and SmallCapVoice.com
AUSTIN, Texas, Feb. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Joe Abdo, CEO of Stella Diagnostics Inc. (OTC Pink: SLDX) (“the...
Extremely Robust Esophageal Cancer Pipeline Expected to Change the Pace of Cancer Treatment as Many Critical Pharma Companies are Proactively Participating in Developing Novel Therapies Estimates DelveInsight
05 oct. 2021 20h00 HE
|
DelveInsight Business Research LLP
Las Vegas, USA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Extremely Robust Esophageal Cancer Pipeline Expected to Change the Pace of Cancer Treatment as Many Critical Pharma Companies are Proactively...
NOTICE TO DISREGARD -- CDx Diagnostics
04 mai 2021 11h13 HE
|
CDx Diagnostics
SUFFERN, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- We are advised by CDx Diagnostics that journalists and other readers should disregard the news release, “CDx Diagnostics Contracts with Wellmark Blue...
WATS3D Receives Medically Necessary Designation from Blue Cross Blue Shield of Kansas City
09 mars 2021 11h00 HE
|
CDx Diagnostics
SUFFERN, N.Y., March 09, 2021 (GLOBE NEWSWIRE) -- WATS3D, a diagnostic platform used by physicians to detect Barrett’s esophagus (BE), pre-cancer and cancerous cells in the esophagus, has received a...
WATS3D Now Considered Medically Necessary by BlueCross BlueShield of South Carolina
26 janv. 2021 14h00 HE
|
CDx Diagnostics
SUFFERN, N.Y., Jan. 26, 2021 (GLOBE NEWSWIRE) -- WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to identify precancerous and cancerous cells in the esophagus, is now...
CDx Diagnostics Awarded Federal Supply Schedule Contract
15 déc. 2020 11h30 HE
|
CDx Diagnostics
Veterans now have access to WATS3D life-saving technology in the VA and community settings SUFFERN, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics has been awarded GSA Contract...
Study Confirms WATS3D as Cost-Effective Adjunct to Seattle Protocol
25 août 2020 13h00 HE
|
CDx Diagnostics
The addition of WATS3D to the screening process for BE resulted in approximately 3 fewer cancers and 3 fewer cancer deaths per 1,000 people screened SUFFERN, N.Y., Aug. 25, 2020 (GLOBE NEWSWIRE) --...
CDx Diagnostics Announces Contract with Hawaii Medical Services Association
11 août 2020 14h30 HE
|
CDx Diagnostics
WATS3D diagnostic platform for screening and surveillance ofBarrett’s esophagus now available to 800,000 members SUFFERN, N.Y., Aug. 11, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics, Inc. is now...
Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer
05 mai 2020 09h00 HE
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, May 05, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...